10x Genomics, Inc. ($TXG) Stock Forecast: Down 5.3% Today

What is 10x Genomics, Inc.?

10x Genomics (NASDAQ: TXG) is a biotechnology company specializing in advancing human health through the study of complex biological systems.

Why is 10x Genomics, Inc. going down?

TXG stock is down 5.3% on Mar 27, 2026 15:01

• The decline in TXG stock today may be linked to the CEO's substantial selling of shares, sparking investor worries about the company's future.
• Despite recent stock gains, positive projects like STELA, and raised price targets from analysts, concerns over internal issues or confidence in growth plans may have been hinted at by the CEO's share selling.
• Institutional selling and apprehensions about a new AI model could also have played a part in the negative outlook on TXG stock, diverting attention from positive developments and analyst support.

TXG Price Chart

TXG Technical Analysis

TXG News

10x genomics CEO Saxonov sells $288,908 in stock

Serge Saxonov, CEO of 10x Genomics (NASDAQ:TXG), sold 15,000 shares of Class A Common Stock for a total of $288,908 on March 23 and 24, 2026. These transactions, executed under a pre-arranged trading plan, occurred as TXG shares have significantly risen. The company has also been involved in new initiatives like the STELA project and received increased price targets from analysts, despite ARK Invest selling shares and concerns about a new AI model.

https://m.investing.com/news/insider-trading-news/10x-genomics-ceo-saxonov-sells-288908-in-stock-93CH-4581088?ampMode=1

10x Genomics (NASDAQ: TXG) CEO sells 15,000 shares under Rule 10b5-1 plan

10x Genomics, Inc. CEO Serge Saxonov sold a total of 15,000 shares of Class A Common Stock over two days, March 23 and March 24, 2026, under a pre-arranged Rule 10b5-1 trading plan. The sales were executed at weighted average prices of $19.1297 and $19.5223 per share, respectively. Following these transactions, Saxonov directly holds 1,172,273 Class A shares, along with significant indirect and Class B holdings through various trusts.

https://www.stocktitan.net/sec-filings/TXG/form-4-10x-genomics-inc-insider-trading-activity-809c0b0eccfa.html

10x genomics CEO Saxonov sells $288,908 in stock

Serge Saxonov, CEO of 10x Genomics, Inc. (NASDAQ:TXG), sold 15,000 shares of Class A Common Stock for a total of $288,908 on March 23 and 24, 2026. These transactions, executed under a pre-arranged trading plan, occurred after significant stock gains for TXG. The company is also involved in several key developments, including a large-scale spatial biology initiative and price target raises from multiple analysts, alongside some institutional selling and concerns about new AI models.

https://www.investing.com/news/insider-trading-news/10x-genomics-ceo-saxonov-sells-288908-in-stock-93CH-4581088

Vanguard amends 13G for 10X Genomics (NASDAQ: TXG) reporting 0 shares

Vanguard has filed an amendment to its Schedule 13G for 10x Genomics (NASDAQ: TXG), reporting beneficial ownership of 0 shares, representing 0% of the class. The filing clarifies that while Vanguard and its managed accounts have rights to dividends or sale proceeds, they do not hold a greater than 5% interest in the company. This amendment updates Vanguard's position as a passive investor, indicating no sole or shared voting or dispositive power over TXG shares.

https://www.stocktitan.net/sec-filings/TXG/schedule-13g-a-10x-genomics-inc-amended-passive-investment-disclosure-3ee4da0c7e3f.html

Trending Today

Brent Crude Oil ($BRENT) Commodity Forecast: Down 7.1% Today

Silver ($XAG) Commodity Forecast: Up 6.1% Today

Chemours Company (The) ($CC) Stock Forecast: Down 5.1% Today

Blink Charging Co. ($BLNK) Stock Forecast: Down 9.1% Today

Sysco Corporation ($SYY) Stock Forecast: Down 5.0% Today

Corning Incorporated ($GLW) Stock Forecast: Down 8.0% Today

Microchip Technology Incorporated ($MCHP) Stock Forecast: Down 5.2% Today

Amphenol Corporation ($APH) Stock Forecast: Down 5.1% Today

ARM Holdings plc ($ARM) Stock Forecast: Down 5.2% Today

KLA-Tencor Corporation ($KLAC) Stock Forecast: Down 5.1% Today

10x Genomics, Inc. Price History

25.01.2026 - TXG Stock was up 5.1%

• TXG experienced a strong bullish movement today, potentially driven by positive developments in its research and development pipeline.
• Despite the challenges faced by the overall life sciences sector in raising capital, TXG's ability to secure funding or announce breakthroughs may have boosted investor confidence.
• The bullish movement could also be attributed to market expectations of TXG's future growth potential and innovation within the industry, leading to increased investor interest and buying activity.

13.01.2026 - TXG Stock was up 10.3%

• Recently, the company demonstrated narrowed losses in 2025, signaling improved profitability and reduced operating expenses, potentially enhancing investor confidence in its financial stability.
• Despite conservative revenue forecasts for 2026 and expectations of modest growth, the company appears to be focusing on profitability and sustainable development, a strategy that investors seem to favor.
• Favorable perceptions of the company's strong cash reserves and strategic partnerships are likely driving positive expectations for its future performance, influencing the upward movement of its stock price today.

21.09.2025 - TXG Stock was up 5.7%

• 10x Genomics (TXG) stock experienced a robust bullish movement, rising by 11.1%.
• The recent above-average trading volume suggests growing investor interest in the company's stock.
• Despite the positive performance, there are concerns about the sustainability of this strength in the short term given recent trends in earnings estimate revisions, which may prompt caution among investors.
• It is advisable for investors to closely track any updates in earnings estimates to assess the future direction of TXG's stock price.

06.02.2026 - TXG Stock was down 5.0%

• The bearish movement in TXG's stock price could be attributed to the CEO selling a significant number of shares, which might have raised concerns among investors about the company's future prospects.
• The filing of a Form 144 by an affiliate proposing to sell Class A Common stock could have also contributed to the downward pressure on the stock, signaling potential insider sentiment or profit-taking.
• Despite the recent strong earnings and raised price targets by analysts, the selling activity by key company figures and affiliates may have created uncertainty among investors, leading to the bearish market movement in TXG today.
• The influx of RSUs being granted to company directors and officers, while designed for retention and performance alignment, could also have added to the selling pressure on the stock as recipients may choose to liquidate some of their holdings.

20.02.2026 - TXG Stock was up 5.4%

• The bullish movement in TXG could be attributed to the positive sentiment surrounding the company's innovative technologies in biological analysis, which are in high demand by various institutions.
• Technical analyses and trade ideas may have also contributed to increased investor confidence in the stock, leading to a surge in buying activity.
• The focus on genomics and biotechnology companies like 10x Genomics in ETF holdings, as seen in the Ark Genomic Revolution UCITS ETF (AAKG), could have further bolstered interest and investment in TXG, driving its bullish movement.

25.02.2026 - TXG Stock was up 8.8%

• An amendment to Schedule 13G by Vanguard for 10X Genomics indicates a potential shift in investment strategy or portfolio reallocation.
• The disclosure that Vanguard holds 0 shares in TXG may have eased concerns about market influence or regulatory issues, boosting investor confidence.
• This update likely contributed to the positive movement in TXG's stock, showcasing stability and transparency in the company's shareholder base and appealing to market participants.

07.10.2025 - TXG Stock was up 11.4%

• The strong bullish movement in TXG today can be attributed to the company's impressive Q3 earnings report, where they beat revenue estimates by 4.64%.
• Investors seem to be optimistic about TXG's future prospects, as the company also reported a positive earnings surprise of 18.52% for the quarter.
• The market's positive reaction indicates confidence in TXG's ability to continue delivering strong financial performance and innovation in the biotechnology sector.

17.01.2026 - TXG Stock was up 5.1%

• The bullish movement in TXG's stock today can be attributed to the company's impressive financial performance in 2025, with significantly narrowed losses and a strategic shift towards profitability.
• The cautious revenue guidance for 2026, projecting modest growth, might have initially raised concerns among investors, but the market likely responded positively to the company's strong cash reserves and strategic partnerships.
• Despite the broader underperformance of the life sciences tools and services sector and economic uncertainties related to tariffs and corporate tax changes, TXG's focus on improved profitability seems to have resonated well with investors, driving the bullish movement in its stock.

09.00.2026 - TXG Stock was up 5.2%

• Analysts raising price targets for TXG led to a 2.5% increase in its stock price, indicating growing optimism in the company's future prospects.
• The market reaction, settling for a 0.7% rise, suggests that while the news was viewed positively, it was not seen as a game-changer for the volatile stock.
• Factors such as recovering end markets and diminishing headwinds contributed to the bullish movement in TXG's stock price.
• The overall sentiment towards TXG seems positive, with analysts expecting a bright outlook for the company in early 2026.

30.09.2025 - TXG Stock was down 5.2%

• The bearish movement in TXG today could be attributed to profit-taking by investors who may have been anticipating a positive earnings report.
• Despite expectations of beating earnings estimates, market sentiment may have shifted due to broader economic concerns or sector-specific challenges impacting biotech stocks.
• It's possible that some investors are taking a cautious approach ahead of the earnings release, leading to a temporary dip in TXG's stock price.

27.02.2026 - TXG Stock was down 5.3%

• The decline in TXG stock today may be linked to the CEO's substantial selling of shares, sparking investor worries about the company's future.
• Despite recent stock gains, positive projects like STELA, and raised price targets from analysts, concerns over internal issues or confidence in growth plans may have been hinted at by the CEO's share selling.
• Institutional selling and apprehensions about a new AI model could also have played a part in the negative outlook on TXG stock, diverting attention from positive developments and analyst support.

19.02.2026 - TXG Stock was up 5.1%

• The bullish movement in TXG stock today could be attributed to positive sentiment in the biotechnology sector, driven by advancements in genomic technologies and their increasing importance in various industries.
• Listing the holdings of the Ark Genomic Revolution UCITS ETF (AAKG) may have highlighted the strong presence of genomics companies like Twist Bioscience Corp. and CRISPR Therapeutics AG, which could have boosted investor confidence in companies like TXG that operate in a similar space.
• Investors may view TXG as a promising player in the genomics industry, especially with the growing focus on healthcare innovation and personalized medicine, leading to increased buying interest and driving the stock price higher.